Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951701 | 0.80 | KMT2A (0.37) | KMT2AMAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL2201874 | 0.79 | SIGMAR1 (0.33) | KMT2AMAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL2204034 | 0.78 | CA2 (0.42) | — | |
| SCHEMBL2201877 | 0.78 | SMN1; SMN2 (0.45) | KMT2AMAPTNPSR1LMNARAB9A | |
| SCHEMBL4951705 | 0.76 | MAPT (0.33) | KMT2AMAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL12426462 | 0.74 | KMT2A (0.45) | KMT2AMAPTLMNARAB9A | |
| SCHEMBL2201911 | 0.71 | CXCR4 (0.34) | — | |
| SCHEMBL2201909 | 0.71 | CXCR4 (0.34) | — | |
| SCHEMBL7573472 | 0.64 | MAPT (0.41) | KMT2AMAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL7573468 | 0.64 | MAPT (0.41) | KMT2AMAPTGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | BCAT2, BCAT1, MRPL9 | KMT2A 2823/4885SLC6A4 405/4885MAPT 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.